
Kidney Cancer Drugs Global Market Report 2025
Description
Kidney Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for kidney cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users
Subsegments:
1) By Renal Cell Carcinoma (RCC): Targeted Therapies; Immune Checkpoint Inhibitors; Cytokine Therapies
2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents; Immunotherapy Agents; Antibody-Drug Conjugates (ADCs)
Companies Mentioned: Pfizer Inc.; Novartis AG; ExelixisInc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
This report focuses on kidney cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for kidney cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The kidney cancer drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users
Subsegments:
1) By Renal Cell Carcinoma (RCC): Targeted Therapies; Immune Checkpoint Inhibitors; Cytokine Therapies
2) By Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC): Chemotherapy Agents; Immunotherapy Agents; Antibody-Drug Conjugates (ADCs)
Companies Mentioned: Pfizer Inc.; Novartis AG; ExelixisInc.; F. Hoffmann-La Roche AG; Bristol Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
175 Pages
- 1. Executive Summary
- 2. Kidney Cancer Drugs Market Characteristics
- 3. Kidney Cancer Drugs Market Trends And Strategies
- 4. Kidney Cancer Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market
- 5. Global Kidney Cancer Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Kidney Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Kidney Cancer Drugs Market Growth Rate Analysis
- 5.4. Global Kidney Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Kidney Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Kidney Cancer Drugs Total Addressable Market (TAM)
- 6. Kidney Cancer Drugs Market Segmentation
- 6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Renal Cell Carcinoma
- Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC)
- 6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Nexavar (Sorafenib)
- Sutent (Sunitinib)
- Afinitor (Everolimus)
- Votrient (Pazopanib)
- Avastin (Bevacizumab)
- Inlyta (Axitinib)
- Other Products
- 6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Research Center
- Other End-Users
- 6.4. Global Kidney Cancer Drugs Market, Sub-Segmentation Of Renal Cell Carcinoma (RCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Targeted Therapies
- Immune Checkpoint Inhibitors
- Cytokine Therapies
- 6.5. Global Kidney Cancer Drugs Market, Sub-Segmentation Of Transitional Cell Carcinoma (TCC) Or Urothelial Cell Carcinoma (UCC), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy Agents
- Immunotherapy Agents
- Antibody-Drug Conjugates (ADCs)
- 7. Kidney Cancer Drugs Market Regional And Country Analysis
- 7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Kidney Cancer Drugs Market
- 8.1. Asia-Pacific Kidney Cancer Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Kidney Cancer Drugs Market
- 9.1. China Kidney Cancer Drugs Market Overview
- 9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Kidney Cancer Drugs Market
- 10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Kidney Cancer Drugs Market
- 11.1. Japan Kidney Cancer Drugs Market Overview
- 11.2. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Kidney Cancer Drugs Market
- 12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Kidney Cancer Drugs Market
- 13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Kidney Cancer Drugs Market
- 14.1. South Korea Kidney Cancer Drugs Market Overview
- 14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Kidney Cancer Drugs Market
- 15.1. Western Europe Kidney Cancer Drugs Market Overview
- 15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Kidney Cancer Drugs Market
- 16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Kidney Cancer Drugs Market
- 17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Kidney Cancer Drugs Market
- 18.1. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Kidney Cancer Drugs Market
- 19.1. Italy Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Kidney Cancer Drugs Market
- 20.1. Spain Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Kidney Cancer Drugs Market
- 21.1. Eastern Europe Kidney Cancer Drugs Market Overview
- 21.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Kidney Cancer Drugs Market
- 22.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Kidney Cancer Drugs Market
- 23.1. North America Kidney Cancer Drugs Market Overview
- 23.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Kidney Cancer Drugs Market
- 24.1. USA Kidney Cancer Drugs Market Overview
- 24.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Kidney Cancer Drugs Market
- 25.1. Canada Kidney Cancer Drugs Market Overview
- 25.2. Canada Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Kidney Cancer Drugs Market
- 26.1. South America Kidney Cancer Drugs Market Overview
- 26.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Kidney Cancer Drugs Market
- 27.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Kidney Cancer Drugs Market
- 28.1. Middle East Kidney Cancer Drugs Market Overview
- 28.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Kidney Cancer Drugs Market
- 29.1. Africa Kidney Cancer Drugs Market Overview
- 29.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles
- 30.1. Kidney Cancer Drugs Market Competitive Landscape
- 30.2. Kidney Cancer Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. ExelixisInc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 31. Kidney Cancer Drugs Market Other Major And Innovative Companies
- 31.1. Bayer AG
- 31.2. Merck & Co., Inc.
- 31.3. EUSA Pharma Inc.
- 31.4. UroGen Pharma Ltd.
- 31.5. Natco Pharma
- 31.6. CStone Pharma
- 31.7. CARsgen Therapeutics
- 31.8. JW Therapeutics
- 31.9. BeiGene
- 31.10. Takeda Pharmaceuticals
- 31.11. Astellas Pharma Inc
- 31.12. Otsuka Pharmaceutical Co., Ltd
- 31.13. Daiichi Pharmaceutical and Sankyo
- 31.14. AstraZeneca plc
- 31.15. GlaxoSmithKline plc
- 32. Global Kidney Cancer Drugs Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market
- 34. Recent Developments In The Kidney Cancer Drugs Market
- 35. Kidney Cancer Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Kidney Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Kidney Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Kidney Cancer Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.